2, 4 Low-grade ICANS is treated with corticosteroids, with escalating doses for high-grade reactions. Other toxicities can coexist with CRS and ICANS Immune compromise, tumour flare, tumour lysis ...
Hosted on MSN1mon
Pasithea's PAS-004 advances in cancer trial with no toxicitiesPasithea's CEO, Dr. Tiago Reis Marques, expressed optimism about the safety profile of PAS-004, a macrocyclic MEK inhibitor with a half-life exceeding 60 hours. The company, whose stock is ...
Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...
Experts discuss practical strategies used by their institutions to manage treatment-related toxicities with third-line therapies for metastatic colorectal cancer (mCRC) and share their experiences on ...
Impaired renal function and cisplatin-based regimens as risk factors for neoadjuvant chemotherapy-induced acute kidney injury in muscle-invasive bladder cancer: A multicenter retrospective study. This ...
(UroToday.com) The 2025 SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Peter Clark discussing a first-in-human study of TAR-210 erdafitinib intravesical system in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback